Comphya

Comphya is developing an active implantable medical device to restore the erectile function of patients non-responsive to oral drugs (e.g. Viagra or Cialis). To achieve an erection, these patients have to resort to intrapenile injections of vasodilators or penile implants, which are quite problematic and outdated. Thus, there is a clear need for better modalities for these patients. Comphya's main focus is spinal cord injury (SCI) and prostatectomy patients.
Rodrigo Fraga-Silva about Verve Ventures
Verve Ventures' support has been of unique importance for the development of Comphya. They not only led our financial round, making it successful, but also helped us set up the company, challenge us on strategical partnerships and increased our network. A good example of Verve Ventures' continuous support is the Entrepreneur Club, which is a great initiative for practical exchanges in a singular environment.
Founders / Management Rodrigo Fraga-Silva, Nikos Stergiopulos, Mikaël Sturny
Sectors Health & Bio, Medtech, Medical Devices
Located in Switzerland
Co-Investors ZKB
Follow On

LinkedIn

Sign up to receive our weekly newsletter and learn about investing in technologies that are changing the world.